Reports Q1 revenue $737.8M, consensus $726.89M. “We are pleased with our solid start to 2024,” said CEO Liam Kelly. “In the quarter, we drove strong execution with constant currency growth and margin expansion year-over-year, executed against our new product launch objectives, and remained on track with our integration of Palette Life Sciences AB. Our Q1 performance, combined with an improving macro-environment, keeps us well-positioned to deliver on our financial guidance for 2024.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFX:
- Teleflex Announces Multiple Clinical and Real-World Evidence Studies to Be Highlighted at the 2024 American Urological Association Annual Meeting
- Teleflex Announces the Limited Market Release of the Wattson™ Temporary Pacing Guidewire
- Teleflex to Present at the BofA Securities 2024 Health Care Conference
- Teleflex Announces First Quarter 2024 Earnings Conference Call Information
- Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue